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Background: Canakinumab, a fully human anti-IL-1b antibody has
been shown to control inflammation in gouty arthritis. This study
evaluated changes in health-related quality of life (HRQoL) in patients
treated with canakinumab or triamcinolone acetonide (TA).
Methods: An 8-wk, dose-ranging, active controlled, single-blind study
in patients (18 to 80 years) with acute gouty arthritis flare, refractory
to or contraindicated to NSAlDs and/or colchicine, were randomized to
canakinumab 10, 25, 50, 90, 150 mg sc or TA 40 mg im. HRQoL was
assessed using patient reported outcomes evaluating PCS and MCS,
and subscale scores of SF-36 [acute version 2]) and functional
disability (HAQ-DI).
Results: In canakinumab 150 mg group, the most severe impairment
at baseline was reported for physical functioning and bodily pain;
levels of 41.5 and 36.0, respectively, which improved in 7 days to 80.0
and 72.2 (mean increases of 39.0 and 35.6) and at 8 wks improved to
86.1 and 86.6 (mean increases of 44.6 and 50.6); these were higher
than levels seen in the general US population. TA group, showed less
improvement in 7 days (mean increases of 23.3 and 21.3 for physical
function and bodily pain). Functional disability scores, measured by
the HAQ-DI decreased in both treatment groups (Table 1).
Conclusions: Gouty arthritis patients treated with canakinumab
showed a rapid improvement in physical and mental well-being
based on SF-36 scores. In contrast to the TA group, patients treated
with canakinumab showed improvement in 7 days in physical function
and bodily pain approaching levels of the general population.
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Background: Gout patients initiating urate lowering therapy have an
increased risk of flares. Inflammation in gouty arthritis is induced by
interleukin (IL)-1b. Canakinumab inhibits IL-1b effectively in clinical
studies. This study compared different doses of canakinumab vs
colchicine in preventing flares in gout patients initiating allopurinol
therapy.
Methods: In this 24 wk double blind study, gout patients (20-79 years)
initiating allopurinol were randomized (1:1:1:1:1:1:2) to canakinumab
s.c. single doses of 25, 50, 100, 200, 300 mg, or 150mg divided in
doses every 4 wks (50þ50þ 25þ25 mg [q4wk]) or colchicine 0.5 mg
p.o. daily for 16 wks. Primary outcome was to determine the
canakinumab dose giving comparable efficacy to colchicine with
respect to number of flares occurring during first 16 wks. Secondary
outcomes included number of patients with flares and C-reactive
protein (CRP) levels during the first 16 wks.
Results: 432 patients were randomized and 391 (91%) completed the
study. All canakinumab doses were better than colchicine in
preventing flares and therefore, a canakinumab dose comparable to
colchicine couldn’t be determined. Based on a negative binomial
model, all canakinumab groups, except 25 mg, reduced the flare rate
ratio per patient significantly compared to colchicine group (rate ratio
estimates 25 mg 0.60, 50 mg 0.34, 100 mg 0.28, 200 mg 0.37, 300 mg
0.29, q4wk 0.38; p 0.05). Percentage of patients with flares was
lower for all canakinumab groups (25 mg 27.3%, 50 mg 16.7%, 100 mg
14.8%, 200 mg 18.5%, 300 mg 15.1%, q4wk 16.7%) compared to
colchicine group (44.4%). All patients taking canakinumab were
significantly less likely to experience at least one gout flare than
patients taking colchicine (odds ratio range [0.22 - 0.47]; p 0.05 for
all). Median baseline CRP levels were 2.86 mg/L for 25 mg, 3.42 mg/L
for 50 mg, 1.76 mg/L for 100 mg, 3.66 mg/L for 200 mg, 3.21 mg/L for
TABLE 1. Comparison of HRQoL scores of gouty arthritis patients treated with canakinumab and triamcinolone acetonide
Component General US
populationa
Canakinumab 150 mg s.c. Triamcinolone acetonide 40 mg i.m.
Baseline N¼27 7 days post-dose N¼ 26y Baseline N¼ 56 7 days post-dose N¼ 54y
Score Score Change from
baseline
Score Score Change from
baseline
SF-36 scores (0-100)
Physical Component Summary
Score (PCS)
50.0# (10.0) 36.4 (8.2) 48.3 (8.6) 12.0 (10.0) 33.5 (9.2) 41.9 (9.4) 8.5 (10.4)
Mental Component Summary
Score (MCS)
50.0# (10.0) 46.7 (13.6) 50.7 (11.2)* 3.4 (11.0) 44.7 (15.1) 47.9 (12.4) 2.9 (13.5)
SF-36 subscale scores
Physical functioning 84.2 (23.3) 41.5 (30.2) 80.0 (25.5) 39.0 (30.9) 38.4 (26.5) 61.5 (29.3) 23.3 (34.6)
Role-physical 80.9 (34.0) 53.0 (32.5) 71.2 (26.8) 18.3 (28.7) 43.2 (25.4) 60.5 (29.0) 17.4 (32.4)
Bodily Pain 75.2 (23.7) 36.0 (26.6) 72.2 (22.0) 35.6 (38.8) 32.4 (25.7) 53.7 (28.6) 21.3 (35.3)
General health 71.9 (20.3) 65.4 (18.0) 71.2 (18.5) 4.6 (8.6) 56.0 (20.2) 61.8 (20.7) 5.5 (18.3)
Vitality 60.9 (20.9) 53.9 (20.5) 66.6 (18.5)* 12.3 (19.5) 48.9 (25.3) 58.6 (25.5) 9.8 (24.7)
Social functioning 83.3 (22.7) 61.6 (32.1) 81.7 (23.5) 18.8 (28.3) 52.5 (29.9) 70.1 (28.3) 17.1 (32.5)
Role-emotional 81.3 (33.0) 63.9 (32.6) 80.8 (25.0) 16.3 (32.1) 66.5 (31.5) 72.1 (27.4) 6.2 (33.3)
Mental health 74.7 (18.1) 67.4 (21.1) 78.1 (18.2)* 9.6 (14.4) 60.5 (25.1) 68.5 (22.8) 8.5 (23.3)
HAQ-DI (0-3) NA 0.8 (0.7) 0.3 (0.4) -0.5 (0.7) 1.1 (0.7) 0.6 (0.6) 0.5 (0.5)
Mean (S.D.) values are presented throughout; ysome scores evaluations were missing for up to 3 patients of the group; #normalized scores representing an average US
person with no chronic disease; *reached general population levels; NA: not available. Reference: a Adapted from Ware J et al. SF-36 Physical and Mental Health
Summary Scales: A User’s Manual, Boston, MA: The Health Institute. 1994
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300 mg, 3.23 mg/L for q4wk canakinumab groups and 2.69 mg/L for
colchicine group. In all canakinumab groups with median CRP levels
above the normal range at baseline, median levels declined within 15
days of treatment and were maintained at normal levels (ULN¼3 mg/L)
throughout the 16 wk period. Adverse events (AEs) occurred in 52.7%
(25 mg), 55.6% (50 mg), 51.9% (100 mg), 51.9% (200 mg), 54.7%
(300 mg), 58.5% (q4wk) of patients on canakinumab vs 53.7% of
patients on colchicine. Serious AEs (SAE) were reported in 2 (3.6%;
25 mg), 2 (3.7%, 50 mg), 3 (5.6%, 100 mg), 3 (5.6%, 200 mg), 3 (5.7%,
300 mg), 1 (1.9%, q4wk) patients on canakinumab and in 5 (4.6%)
patients on colchicine. 1 fatal SAE (myocardial infarction, not related to
study drug) occurred in colchicine group.
Conclusions: In this randomized, double-blind active controlled study
of flare prevention in gout patients initiating allopurinol therapy,
treatment with canakinumab led to a statistically significant reduction
in flares compared with colchicine and was well tolerated.
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Background: Septic arthritis is a common condition that carries a high
degree of mortality and morbidity. Traditionally, however, its manage-
ment has been shown to be sub-optimal. Various studies have descri-
bed some or all of: a lack of or delay in joint aspiration, antibiotics
being started prior to joint aspiration, blood cultures not being sent,
synovial fluid not being sent for crystal analysis, and a lack of or delay
in specialist referral. This has often resulted in a muddying of the
diagnosis and as a result extended lengths of hospital stay. It has been
suggested that at the root of this lies a significant lack of knowledge
of the BSR guidelines amongst doctors in medical and surgical
specialties. To add to the body of work that exists in this area, I tested
this suggestion by surveying the junior doctors in my hospital on their
knowledge of the BSR guidelines.
Methods: I devised ten true or false questions based on the BSR
guidelines for the management of the hot swollen joint in adults, 2006.
I prefaced them with a short clinical vignette ending in the summary,
‘‘The clinical suspicion is high for septic arthritis.’’ The questions were
then issued to each doctor in the hospital below ST3 level in medicine,
surgery and A&E. Some were completed and returned via e-mail, but
the majority were done at the end of group teaching sessions. All
participants were asked to give their answers without using external
resources.
Results: 63 doctors participated from F1 to CT2 grades (22¼F1,
20¼ F2, 14¼CT1, 7¼CT2). The majority of F1 and F2 doctors were
working in medicine (24) with 10 currently working in surgery and the
rest in A&E or GP. 18 of the core trainees were working in medicine,
the other 3 working in A&E. See Table 1 for results.
Conclusions: Knowledge of the BSR guidelines is patchy in this group
of junior doctors. There is a significant proportion who are unaware
that blood cultures and fluid for crystals should always be sent while
nearly half are unaware that fluid should be aspirated prior to starting
antibiotics. These findings are supportive of the suggestion that a lack
of knowledge of the guidelines explains the sub-optimal management
reported elsewhere. Given that this is predictive and perhaps repre-
sentative of poor adherence locally, I have presented these findings,
run a joint injection workshop and are introducing a treatment
algorithm to ensure best practice.
Disclosure statement: The author has declared no conflicts of
interest.
TABLE 1. PERCENTAGE CORRECT ANSWERS PER QUESTION
F1 F2 CT1/CT2
Treat even in absence of fever 95 90 85
Must aspirate before starting antibiotics 41 65 52
Warfarin is not a contraindication 41 70 81
Refer to Orthopaedics if prosthetic 95 80 76
Not excluded if gram stain negative 95 100 90
Not excluded if culture negative 45 60 71
Always perform microscopy for crystals 72 80 85
Always perform blood cultures 91 80 95
Urate levels are of no diagnostic value 27 40 66
X-ray is of no diagnostic value 45 30 28
115. POLYMYALGIA RHEUMATICA: DIAGNOSIS,
PRESCRIBING AND MANAGEMENT IN PRIMARY CARE
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Background: Polymyalgia rheumatica (PMR) is the most common
inflammatory rheumatological disorder affecting elderly Caucasians.
Studies of polymyalgia rheumatica have centred largely on patients
recruited from secondary and specialist care settings yet the majority
of patients are diagnosed and managed solely in primary care. In the
very few primary care studies undertaken, it has been shown that there
is wide variation in practice and established diagnostic criteria are
infrequently used. Our study aims to clarify further, and compare with
the most up to date guidelines, the diagnostic processes and
management of polymyalgia rheumatica in the primary care setting.
Methods: Using the two linked regional databases (Consultations in
Primary Care Archive (CiPCA) and Prescriptions in Primary Care
Archive (PiPCA) at the Primary Care Sciences department at Keele
University, patients with PMR were identified by Read code. Using the
latest guidelines, areas for review were identified and the relevant data
from the database’s frozen consultations, prescription data and
investigation results was extracted.
Results: Documentation of symptoms was clearly present in 82.2% of
cases with the most common primary symptom being the classical
bilateral shoulder pain (45.7%). A documented process of exclusion
was seen in just 22.4% of cases and a standard response to steroids
was seen in 72.7%. The mean initial dose was 21.5 mg of prednisolone
although the modal dose was 15 mg. 22.9% were diagnosed with an
ESR of less than 30. The average duration of illness was 19 months
ranging from 0 to 96 months. Referral was made in 45.4% of cases
although in the great majority of those referred it was unclear why they
were referred.
Conclusions: Compared to previous studies, referral rates are higher,
initial steroid doses are appropriate and documentation is improving.
Clear areas for improvement would include better documentation of a
process of exclusion to rule out more sinister pathologies and early
referral of patients to specialist care for those who do not fit the
‘‘normal’’ PMR picture.
Disclosure statement: The authors have declared no conflicts of
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116. THE PREVALENCE OF VITAMIN D DEFICIENCY IN
RHEUMATOLOGY OUTPATIENTS PRESENTING WITH
ARTHRALGIA, MYALGIA OR FATIGUE
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Background: Vitamin D deficiency is classically associated with
childhood ricketts and osteomalacia in adults due to its importance in
the maintenance of calcium and phosphate homeostasis. However,
over the past few years, low vitamin D levels have been shown to be
associated with a various disorders ranging from colorectal cancer,
through multiple sclerosis to Type I Diabetes. Within the field of
rheumatology, in addition to osteoporosis, vitamin D deficiency is
linked to the onset of RA, connective tissue disorders and chronic
widespread pain.
The aim of the study was to determine the prevalence of vitamin D
deficiency in these patients.
Methods: It is the usual practice of one of our consultants (PH) to
check vitamin D status in patients presenting with polyarthralgia,
polymyalgia or fatigue regardless of their primary rheumatological
diagnosis. 25 hydroxyvitamin D levels were measured in such patients
attending our rheumatology clinics in a 3 month period between
August and November 2010.
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